Fancy Meds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fancymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   ““Same active ingredient as Ozempic and Wegovy””

2. 2

   ““Compounding semaglutide involves creating small, customized batches of the medication in an FDA-monitored, state-licensed pharmacy, using FDA-approved ingredients….””

3. 3

   ““Though they contain the same active ingredient as branded Ozempic and Wegovy, compounded versions are much more affordable, so you win!””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

fancymeds.com returned a live storefront when we checked in August 2026, running a checkout discount code and advertising first-month prices for semaglutide and tirzepatide. We did not review every page on the site.

"So you win!" is the whole argument of the compounded GLP-1 market compressed into three words, and this is the one letter in the wave where FDA quoted it directly. The sentence works by conceding nothing: same ingredient, lower price, therefore pure gain. What the letter points out is that the first half is what makes the second half persuasive, and the first half is the part FDA disputes — the compounded product is not the approved one, so "same" is carrying weight it cannot hold. The separate claim about an "FDA-monitored" pharmacy using "FDA-approved ingredients" does similar work on the supply chain. None of this is a finding about the medication itself. It is a finding about an argument. A lower price is still a lower price; it is just not a free one, and the letter is a reminder to price the difference rather than assume it away.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Fancy Meds failed to respond.